Skip to Main Content

Advertisement intended for health care professionals

Skip Nav Destination

Phase 1/2 study of uproleselan added to chemotherapy in patients with relapsed or refractory acute myeloid leukemia

Blood (2022) 139 (8): 1135–1146.
Currently there are no citedby results. Try again later.
Close Modal

or Create an Account

Close Modal
Close Modal

Advertisement intended for health care professionals